Galectin Therapeutics (GALT) Research & Development (2010 - 2026)

Galectin Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Research & Development fell 65.6% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $10.0 million (down 71.33% YoY), while the FY2025 annual figure was $14.3 million, down 60.93% from the prior year.
• Research & Development for Q1 2026 stood at $2.2 million, up from $1.9 million in the prior quarter.
• The five-year high for Research & Development was $11.1 million in Q4 2024, with the low at $1.9 million in Q4 2025.
• The 5-year median for Research & Development is $7.7 million (2023), against an average of $6.9 million.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 64.48% in 2022, then plunged 82.6% in 2025.
• Galectin Therapeutics' Research & Development stood at $9.0 million in 2022, then slipped by 8.65% to $8.2 million in 2023, then soared by 35.01% to $11.1 million in 2024, then slumped by 82.6% to $1.9 million in 2025, then gained by 15.42% to $2.2 million in 2026.
• Business Quant data shows GALT's Research & Development at $2.2 million in Q1 2026, $1.9 million in Q4 2025, and $2.6 million in Q3 2025.